Tirzepatide
Mounjaro · Zepbound · LY3298176
A weekly dual-agonist many people compare with semaglutide for appetite.
A dual incretin agonist approved for T2D and weight management. Typically more weight loss than semaglutide in trials, with similar GI titration rules.
Usual range
2.5–15 mg
Schedule
Once weekly
Half-life
~5 days
How it is used
Dual GIP/GLP-1 agonist. Stronger weight effect, same titration logic.
Subcutaneous
Same weekday. Rotate sites.
Ongoing under care. Stay at the lowest effective dose.
How to mix this vial
Typical vial 10 mg · 2 mL BAC
10 mg + 2 mL → 5 mg/mL. 2.5 mg = 50 units. Confirm vial milligrams before mixing.
Fridge. Do not freeze. Branded pens follow label.
Side effects
- Nausea
- Vomiting
- Constipation
- Reflux
- Gallbladder disease
- Muscle loss if under-eating protein
Who should skip this
- MTC / MEN2
- Pregnancy
- Serious GI disease
Nutrition note
Four small protein-forward meals beat two large ones. Stop eating at first fullness. Resistance training is non-negotiable.
Stacks
Often paired with
Approved drug. Compounded tirzepatide is not Zepbound/Mounjaro.
Peptipedia is an educational calculator, not medical advice. Many catalog entries are unapproved for human use. Approved molecules have labels that outrank this app. Do not use this to self-prescribe. Consult a licensed clinician. Not for anyone under 18, pregnant, or being treated for cancer.